Current Therapeutic Strategies of Xeroderma Pigmentosum
- PMID: 35283513
- PMCID: PMC8906321
- DOI: 10.4103/ijd.ijd_329_21
Current Therapeutic Strategies of Xeroderma Pigmentosum
Abstract
Xeroderma pigmentosum (XP) is an autosomal recessive genetic disease caused by a defect in the DNA repair system, exhibiting skin cancer on sun exposure. As it is an incurable disease, therapeutic strategies of this disease are critical. This review article takes an attempt to explore the current therapeutic advancements in XP. Different approaches including sun avoidance; surgical removal of cancerous lesions; laser and photodynamic therapy; use of retinoid, 5-fluorouracil, imiquimod, photolyase, and antioxidant; interferon therapy and gene therapy are chosen by doctors and patients to lessen the adverse effects of this disease. Among these options, sun avoidance, use of 5-fluorouracil and imiquimod, and interferon therapy are effective. However, some approaches including laser and photodynamic therapy, and the use of retinoids are effective against skin cancer having severe side effects. Furthermore, surgical removal of cancerous lesions and use of antioxidants are considered to be effective against this disease; however, efficacies of these are not experimentally determined. In addition, some approaches including oral vismodegib, immunotherapy, nicotinamide, acetohexamide, glimepiride-restricted diet are found to be effective to minimize the complications secondary to defects in the nucleotide excision repair (NER) system and also enhance the NER, which are under experimental level yet. Besides these, gene therapy, including the introduction of missing genes and genome edition, may be a promising approach to combat this disease, which is also not well established now. In the near future, these approaches may be effective tools to manage XP.
Keywords: DNA repair; gene therapy; skin cancer; therapeutic strategies; xeroderma pigmentosum.
Copyright: © 2022 Indian Journal of Dermatology.
Conflict of interest statement
There are no conflicts of interest.
Figures
Similar articles
-
Xeroderma pigmentosum: an updated review.Drugs Context. 2022 Apr 25;11:2022-2-5. doi: 10.7573/dic.2022-2-5. eCollection 2022. Drugs Context. 2022. PMID: 35520754 Free PMC article. Review.
-
Nucleotide Excision Repair: From Molecular Defects to Neurological Abnormalities.Int J Mol Sci. 2021 Jun 9;22(12):6220. doi: 10.3390/ijms22126220. Int J Mol Sci. 2021. PMID: 34207557 Free PMC article. Review.
-
Complementation of the DNA repair deficiency in human xeroderma pigmentosum group a and C cells by recombinant adenovirus-mediated gene transfer.Hum Gene Ther. 2002 Oct 10;13(15):1833-44. doi: 10.1089/104303402760372936. Hum Gene Ther. 2002. PMID: 12396616
-
Sunlight, Vitamin D, and Xeroderma Pigmentosum.Adv Exp Med Biol. 2020;1268:319-331. doi: 10.1007/978-3-030-46227-7_16. Adv Exp Med Biol. 2020. PMID: 32918226 Review.
-
Novel therapeutic approaches to xeroderma pigmentosum.Br J Dermatol. 2019 Aug;181(2):249-255. doi: 10.1111/bjd.17253. Epub 2018 Nov 25. Br J Dermatol. 2019. PMID: 30265743 Review.
Cited by
-
Xeroderma Pigmentosam: Case Report of Siblings.Int J Clin Pediatr Dent. 2025 Mar;18(3):311-316. doi: 10.5005/jp-journals-10005-3083. Epub 2025 Apr 19. Int J Clin Pediatr Dent. 2025. PMID: 40415748 Free PMC article.
-
An unusual presentation of Huntington's disease-like syndrome in a patient with Xeroderma pigmentosum type F: Case report and review of the literature.Clin Park Relat Disord. 2025 May 9;12:100340. doi: 10.1016/j.prdoa.2025.100340. eCollection 2025. Clin Park Relat Disord. 2025. PMID: 40475389 Free PMC article. Review.
-
Whole Exome Sequencing of a Patient with a Milder Phenotype of Xeroderma Pigmentosum Group C.Medicina (Kaunas). 2023 Apr 3;59(4):699. doi: 10.3390/medicina59040699. Medicina (Kaunas). 2023. PMID: 37109656 Free PMC article.
References
-
- Kleijer WJ, Laugel V, Berneburg M, Nardo T, Fawcett H, Gratchev A, et al. Incidence of DNA repair deficiency disorders in western Europe: Xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. DNA Repair (Amst) 2008;7:744–50. - PubMed
-
- Dodd KM, Dunlop EA. Tuberous sclerosis—A model for tumour growth. Semin Cell Dev Biol. 2016;52:3–11. - PubMed
-
- Cleaver JE. Defective repair replication of DNA in xeroderma pigmentosum. Nature. 1968;218:652–6. - PubMed
-
- Hong C, Qing-Qi Y, Chao M, Dong-Xu Z, Yi-Xia W, Ping S, et al. Photodynamic therapy in the treatment of xeroderma pigmentosum: A case report. Photodiagnosis Photodyn Ther. 2020:30. doi: 10.1016/j.pdpdt. 2020.101761. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials